Piramal Pharma Receives US FDA EIR With VAI For Lexington Facility

Piramal Pharma has confirmed that the US Food and Drug Administration (FDA) has completed its inspection of the Lexington facility. The issuance of an EIR with a VAI status marks a positive development for the company, ensuring continued supply and regulatory alignment in the US market.

Inspection Outcome And Compliance

The FDA’s EIR with VAI indicates that while minor observations were noted, no significant regulatory hurdles remain. This closure reinforces Piramal Pharma’s commitment to maintaining high-quality standards and compliance across its global manufacturing network.

Business Impact And Market Confidence

The successful closure of the inspection is expected to boost investor confidence and support Piramal Pharma’s growth in regulated markets. Analysts suggest that the outcome will help sustain product supply chains and enhance credibility with international clients.

Key Highlights

• US FDA issues EIR for Lexington facility
• Inspection closed with VAI classification
• Minor observations, no critical compliance issues
• Strengthens regulatory alignment and market confidence
• Supports Piramal Pharma’s global supply chain operations

Sources: Piramal Pharma release, US FDA updates, Economic Times, Business Standard